Jena Acquisition Corporation II Receives NYSE Non-Compliance Notice Regarding Minimum Public Shareholders Requirement

Key Points from the Report

• Jena Acquisition Corporation II has received a formal written notice from NYSE Regulation, dated April 1, 2026, indicating non-compliance with Section 802.01B of the NYSE Listed Company Manual.
• This rule mandates that listed companies maintain a minimum of 300 public stockholders on a continuous basis.
• The company currently does not meet this requirement, putting its NYSE listing at risk.
• Jena Acquisition Corporation II intends to submit a business plan to NYSE detailing how it expects to regain compliance within 18 months, primarily through completing a de-SPAC transaction.
• There is no immediate impact on the company’s securities; provided NYSE approves the plan, Jena’s shares will remain listed and tradable during the 18-month cure period under existing ticker symbols.
• The company is a blank check entity, incorporated in the Cayman Islands, formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
• Management intends to capitalize on their expertise, especially those of co-founder and Chairman William P. Foley II and CEO Richard N. Massey, to identify suitable targets for a business combination.

Important Information for Shareholders

• Risk of Delisting: If Jena Acquisition Corporation II fails to regain compliance with NYSE’s minimum public stockholder requirement within the designated 18 months, its shares could be delisted, which would significantly impact liquidity and shareholder value.
• De-SPAC Transaction: Management’s primary plan to return to compliance is to complete a de-SPAC transaction. Success in this regard could increase the number of public shareholders and potentially enhance share value, but failure could put the listing in jeopardy.
• No Immediate Impact: The NYSE notice does not immediately affect trading or listing status. Investors can continue to trade Jena’s shares during the cure period, but should monitor developments closely.
• Forward-Looking Statements: The company’s ability to submit an adequate plan and regain compliance is subject to risks and uncertainties, including approval by NYSE Regulation and successful execution of a business combination.
• Management Expertise: Shareholders may take comfort in the experienced leadership team, including Chairman William P. Foley II and CEO Richard N. Massey, whose track record may improve the odds of a successful outcome.
• Board Members: W. Dabbs Cavin, Dexter Fowler, and Tim Hsia serve as board members, adding further expertise to the company’s governance.

Potential Impact on Share Price

The NYSE non-compliance notice is a material event and could potentially move the share price. The risk of delisting, uncertainty around regaining compliance, and the outcome of the proposed de-SPAC transaction are all factors that investors should weigh carefully. While the immediate impact may be limited due to the cure period, the company’s ability to execute its business plan and maintain its listing status will be watched closely by the market. The notice could create volatility and uncertainty until compliance is achieved.

Forward-Looking Statements & Risks

This report contains forward-looking statements, including expectations regarding submission of a business plan, regaining compliance, completing a de-SPAC transaction, and maintaining NYSE listing status. These statements involve risks and uncertainties, such as approval by NYSE Regulation, execution of a business combination, and meeting the minimum shareholder requirement. Investors should refer to the company’s SEC filings for additional risk factors and not place undue reliance on forward-looking statements.

Contact Information

Media Contact:
Richard N. Massey, CEO
jenaacquisition.com

Disclaimer: This article is for informational purposes only and should not be construed as investment advice. All information is based on publicly disclosed documents and subject to change. Investors should perform their own due diligence and consult professional advisers before making investment decisions. The author assumes no responsibility for investment actions based on this article.

View JENA ACQUISITION Corp II Historical chart here